Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Dietary fish intake increased the concentration of soluble ACE2 in rats: can fish consumption reduce the risk of COVID-19 infection through interception of SARS-CoV-2 by soluble ACE2?The British journal of nutrition · 2023
   Article
2. Reduced Vessel Density and Enlarged Foveal Avascular Zone in the Macula as a Result of Systemic Hypoxia Caused by SARS-CoV-2 Infection.Journal of personalized medicine · 2023
   Review
3. Exploring the potential mechanisms of impairment on genitourinary system associated with coronavirus disease 2019 infection: Bioinformatics and molecular simulation analyses.Asian journal of urology · 2023
   Article
4. Links between COVID-19 and Alzheimer's Disease-What Do We Already Know?International journal of environmental research and public health · 2023
   Review
5. SARS-CoV-2 and Hypertension: Evidence Supporting Invasion into the Brain Via Baroreflex Circuitry and the Role of Imbalanced Renin-Angiotensin-Aldosterone-System.Neuroscience insights · 2023
   Article
6. Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17.Molecules (Basel, Switzerland) · 2022
   Article
7. Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2.Diagnostics (Basel, Switzerland) · 2022
   Article
8. Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls.Frontiers in medicine · 2022
   Article
9. ACE2 Serum Levels as Predictor of Infectability and Outcome in COVID-19.Frontiers in immunology · 2022
   Article
10. The Correlation Between Immune Invasion and SARS-COV-2 Entry Protein ADAM17 in Cancer Patients by Bioinformatic Analysis.Frontiers in immunology · 2022
    Article
11. Is COVID-19 Gender-sensitive?Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021
    Review
12. A Dual-Route Perspective of SARS-CoV-2 Infection: Lung- vs. Gut-specific Effects of ACE-2 Deficiency.Frontiers in pharmacology · 2021
    Review
13. Sex differences in the incidence, mortality, and fatality of COVID-19 in Peru.PloS one · 2021
    Article
14. COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy.Frontiers in endocrinology · 2021
    Review
15. The Renin-Angiotensin System as a Component of Biotrauma in Acute Respiratory Distress Syndrome.Frontiers in physiology · 2021
    Review
16. ACE2: the molecular doorway to SARS-CoV-2.Cell & bioscience · 2020
    Review
17. Does Angiotensin II Peak in Response to SARS-CoV-2?Frontiers in immunology · 2020
    Review

Corrections and comments

• Comment on
  Age and sex differences in soluble ACE2 may give insights for COVID-19.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as